Skip to content

Study Evaluating the Effectiveness of the Use of Prosthesis With Trans-Obturator Way for the Correction of Anterior Prolapse

PERIGEE :Randomized Study Evaluating the Effectiveness of the Use of Prosthesis With Trans-obturator Way for the Correction of Anterior Prolapse.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00859417
Enrollment
78
Registered
2009-03-11
Start date
2008-09-30
Completion date
2013-07-31
Last updated
2019-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Prolapse

Keywords

correction of anterior prolapse, prosthetic trans-obturator way kit, randomized study

Brief summary

The classical surgical treatment of an anterior prolapse is the use of autologous tissue. In front of the high rate of recurrences with this technique, the use of synthetic prosthesis made their appearance. But the drawback of the use of prosthesis is their tolerability. The system Perigee®, a prosthetic kit by trans-obturator way, was designed to obtain high efficiency in the correction of the prolapse while reducing the risk of complications. The lack of prospective and randomized studies makes difficult to assess the interest. The investigators, therefore, have put in place a randomized prospective study seeking the evaluation of the system Perigee® compared to the conventional surgical technique.

Interventions

Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).

DEVICEPerigee® prosthesis

Surgical method with Perigee® prosthesis

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Women over 18 years old * Genital anterior prolapse requiring surgical correction and with stage III or IV in the classification of Pelvic Organ Prolapse - Quantification or POP-Q * Ability to understand the information and to sign a consent form * Patients wishing an intervention because of the inconvenience caused by the prolapse.

Exclusion criteria

* Prolapse stage \<III in the classification POP-Q, and prolapse without functional inconvenience * Progressive or latent infection, or signs of tissue necrosis in the clinical examination * Troubles resulting in an unacceptable risk of post-surgery complications investigated at the interview with the patient (disorders of blood clotting, immune system disorders, progressive diseases….) * Mobility of the lower limbs reduced (not permitting the positioning for the surgery) * Pregnancy or any desire of pregnancy during the study, within two years * Pelvic surgery in the last 6 months * Patients who have had radiotherapy of the pelvic area in an irrespective time * A history of pelvic cancer * Known hypersensitivity to any component of the prosthesis (polypropylene) * Uncontrolled diabetes (HbA1c\> 8%) * Treatment modifying the immune response (immuno-modulators), current or stopped for less than one month * Inability to understand the information and to sign a consent * A person not subject to social security, deprived of freedom, or under legal guardian

Design outcomes

Primary

MeasureTime frame
Correction of prolapse, which is defined by a stage < II on the classification POP-Q, one year after surgery12 months

Secondary

MeasureTime frame
Correction of prolapse 2 years after surgery24 months
Changes in quality of life, occurrence of complications during surgery, evolution of sexuality, onset or worsening of urinary incontinenceat 3,12, 24 months
Pain after surgery24 months
Duration of intervention24 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026